Claude Sonnet 5 agent picks gene therapy and injects mouse brain, per Exin CEO
Overview
Exin Therapeutics CEO Gabriel Ocana-Santero says a Claude Sonnet 5 agent chose a drug, a brain target and stereotactic coordinates on its own, then performed an injection in an epilepsy mouse model.
According to Ocana-Santero, the agent stopped when its target fell outside the device's range of motion, and he fixed the code by hand before the procedure continued.
The results have not been peer-reviewed, and a technical report is expected. The account comes from Ocana-Santero, who is also a PhD student at the University of Oxford, and has not been independently verified.
Written by AI from the articles below · updated Oct 30, 3:51 PM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- The DecoderNewsPickClaude Sonnet 5 chose a gene therapy and operated on a mouse brain without human decisions
AIExin Therapeutics CEO Gabriel Ocana-Santero says a Claude Sonnet 5 agent selected a drug, brain target and coordinates, then performed an injection in an epilepsy mouse model. The agent refused to continue when its target fell outside the device's range of motion, and Ocana-Santero fixed the code by hand. The results have not been peer-reviewed, and a technical report is expected.
Heat Trend
Not enough continuous observations to show a trend yet.